1. Home
  2. ECPG vs CANF Comparison

ECPG vs CANF Comparison

Compare ECPG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Encore Capital Group Inc

ECPG

Encore Capital Group Inc

HOLD

Current Price

$68.96

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$3.02

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECPG
CANF
Founded
1998
1994
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
4.7M
IPO Year
1999
2011

Fundamental Metrics

Financial Performance
Metric
ECPG
CANF
Price
$68.96
$3.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
2
Target Price
$77.33
$9,750.00
AVG Volume (30 Days)
255.6K
643.0K
Earning Date
05-06-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
287.14
N/A
EPS
10.91
N/A
Revenue
$1,768,802,000.00
N/A
Revenue This Year
$4.53
$461.72
Revenue Next Year
$4.76
$290,391.28
P/E Ratio
$6.31
N/A
Revenue Growth
34.37
N/A
52 Week Low
$26.45
$0.17
52 Week High
$74.58
$10.40

Technical Indicators

Market Signals
Indicator
ECPG
CANF
Relative Strength Index (RSI) 57.13 35.07
Support Level $65.01 $0.59
Resistance Level $74.58 $4.74
Average True Range (ATR) 2.17 0.20
MACD -0.33 -0.08
Stochastic Oscillator 55.45 0.85

Price Performance

Historical Comparison
ECPG
CANF

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

Share on Social Networks: